Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects [4]

Leukemia

Volumn 20, Issue 8, 2006, Pages 1441-1445

  Pettitt, Andrew R ^a   Matutes, E ^b   Oscier, D ^c  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALLOPURINOL; ANTIBIOTIC AGENT; CHLORAMBUCIL; CHLORPHENIRAMINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; ITRACONAZOLE; LANSOPRAZOLE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PARACETAMOL; PREDNISOLONE; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLELE; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CYTOMEGALOVIRUS INFECTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FOLLOW UP; GENE DELETION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; LUNG ASPERGILLOSIS; LYMPHADENOPATHY; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEFECT;

EID: 33746137366     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404265     Document Type: Letter

References (8)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
2. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T et al. p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood 1998; 91: 4342-4349.
3. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
4. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
5. Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82: 759-765.
6. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-453.
7. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blond 2004; 103: 3278-3281.
8. Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005; 90: 1435-1436.